Nephronophthisis : Clinical & Genetic Study

Clinical Trial Description

To specify the long term evolution of Nephronophthisis in terms of renal disease as well as extra-renal damages for patients having a confirmed diagnosis of NPHP1, NPHP2, NPHP3, NPHP4, NPHP5, NPHP6 or NPHP8 gene mutation ;

Study Design

Related Conditions & MeSH terms

Nephronophthisis

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04874909` - Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM)	N/A
Recruiting	`NCT06065852` - National Registry of Rare Kidney Diseases
Recruiting	`NCT01401998` - UAB HRFD Core Center: Core A: The Hepato/Renal Fibrocystic Diseases Translational Resource
Recruiting	`NCT05286632` - KidneYou - Innovative Digital Therapy	N/A

See also

Status

Clinical Trial

Phase

Recruiting

NCT04874909 - Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM)

N/A

Recruiting

NCT06065852 - National Registry of Rare Kidney Diseases

Recruiting

NCT01401998 - UAB HRFD Core Center: Core A: The Hepato/Renal Fibrocystic Diseases Translational Resource

Recruiting

NCT05286632 - KidneYou - Innovative Digital Therapy

N/A

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT01022957
Study type	Interventional
Source	Assistance Publique - Hôpitaux de Paris
Contact
Status	Completed
Phase	N/A
Start date	November 2006
Completion date	January 2010

Nephronophthisis : Clinical and Genetic Study — NEPHAER

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms